Cann GroupASX:CAN Stock Report

Market Cap







20 Sep, 2021


Company Financials
CAN fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

CAN Overview

Cann Group Limited operates in the medical cannabis industry in Australia.

Share Price & News

How has Cann Group's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: CAN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CAN's weekly volatility (9%) has been stable over the past year.

Market Performance

7 Day Return




AU Pharmaceuticals


AU Market

1 Year Return




AU Pharmaceuticals


AU Market

Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -3.2% over the past year.

Return vs Market: CAN underperformed the Australian Market which returned 28.8% over the past year.

Shareholder returns

7 Day-1.8%-1.9%-2.7%
30 Day-5.2%7.6%-2.5%
90 Day-28.6%3.3%-0.7%
1 Year-32.9%-32.9%-4.8%-4.9%31.3%26.0%
3 Year-90.1%-90.1%-45.8%-46.0%33.0%16.7%
5 Yearn/a-48.2%-49.2%62.6%30.4%

Long-Term Price Volatility Vs. Market

How volatile is Cann Group's share price compared to the market and industry in the last 5 years?

Simply Wall St News

Cann Group Fundamentals Summary

How do Cann Group's earnings and revenue compare to its market cap?
CAN fundamental statistics
Market CapAU$87.24m
Earnings (TTM)-AU$25.10m
Revenue (TTM)AU$8.53m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CAN income statement (TTM)
Cost of RevenueAU$48.00k
Gross ProfitAU$8.48m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)-0.098
Gross Margin99.44%
Net Profit Margin-294.39%
Debt/Equity Ratio0%

How did CAN perform over the long term?

See historical performance and comparison


Is Cann Group undervalued compared to its fair value and its price relative to the market?


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: CAN is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: CAN is unprofitable, so we can't compare its PE Ratio to the Australian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CAN's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CAN is good value based on its PB Ratio (0.9x) compared to the AU Pharmaceuticals industry average (3.1x).

Future Growth

How is Cann Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cann Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Cann Group performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CAN is currently unprofitable.

Growing Profit Margin: CAN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.

Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).

Return on Equity

High ROE: CAN has a negative Return on Equity (-27.32%), as it is currently unprofitable.

Financial Health

How is Cann Group's financial position?

Financial Position Analysis

Short Term Liabilities: CAN's short term assets (A$22.1M) exceed its short term liabilities (A$9.6M).

Long Term Liabilities: CAN's short term assets (A$22.1M) exceed its long term liabilities (A$271.0K).

Debt to Equity History and Analysis

Debt Level: CAN is debt free.

Reducing Debt: CAN has no debt compared to 5 years ago when its debt to equity ratio was 0%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.1% each year


What is Cann Group current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CAN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CAN's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Peter Crock





Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at Cann Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing an...

CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD265.43K) is about average for companies of similar size in the Australian market ($USD276.85K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CAN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: CAN's board of directors are considered experienced (3.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: CAN insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.7%.

Top Shareholders

Company Information

Cann Group Limited's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Cann Group Limited
  • Ticker: CAN
  • Exchange: ASX
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$87.239m
  • Shares outstanding: 317.23m
  • Website:


  • Cann Group Limited
  • 4 Research Avenue
  • Bundoora
  • Victoria
  • 3083
  • Australia



Cann Group Limited operates in the medical cannabis industry in Australia. It licenses to undertake research and to cultivate cannabis for human medicinal and research purposes. The company was founded in...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 15:32
End of Day Share Price2021/09/20 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.